糖尿病与斋月：简明实用的最新情况
Diabetes and Ramadan: A concise and practical update.
作者信息
Ahmed Mohamed H, Husain Nazik Elmalaika, Elmadhoun Wadie M, Noor Sufian K, Khalil Abbas A, Almobarak Ahmed O
机构信息
Department of Medicine and HIV Metabolic Clinic, Milton Keynes University Hospital NHS Foundation Trust, Eaglestone, Milton Keynes, Buckinghamshire, UK.
Department of Pathology, Faculty of Medicine and Health Sciences, Omdurman Islamic University, Khartoum, Sudan.
出版信息
J Family Med Prim Care. 2017 Jan-Mar;6(1):11-18. doi: 10.4103/2249-4863.214964.
Despite the fact that the month of Ramadan includes 29-30 days and the duration of fasting for each day can last for between 12 and 16 h, it was estimated that a large number of individuals with diabetes do fast during Ramadan. In light of recent advancement of new pharmacological agents, drugs such as vildagliptin, sitagliptin, and liraglutide were found to be safe to use during this month of fasting. These therapeutic agents can also be used in combination with metformin. The use of sulfonylureas, in most of the recent guidelines about diabetes and Ramadan, seems not to gain much support due to the risk of hypoglycemia. In this review, we also addressed the use of insulin injection, insulin pump, and education before, during, and after Ramadan. Further research is needed to determine (i) the therapeutic benefit of new antidiabetic agents and (ii) the benefit of new technologies for the treatment of diabetes.
尽管斋月为期29至30天，且每天的禁食时长可达12至16小时，但据估计，仍有大量糖尿病患者在斋月期间禁食。鉴于新药理学药物的最新进展，发现维格列汀、西他列汀和利拉鲁肽等药物在这个禁食月使用是安全的。这些治疗药物也可与二甲双胍联合使用。在大多数最新的糖尿病与斋月指南中，由于存在低血糖风险，磺脲类药物的使用似乎未得到太多支持。在本综述中，我们还探讨了斋月前、期间和之后胰岛素注射、胰岛素泵的使用以及教育情况。需要进一步研究以确定：（i）新型抗糖尿病药物的治疗益处；（ii）糖尿病治疗新技术的益处。
Zotero 插件